RELX (ADR) (RELX)
Embeds proprietary data and analytics in professional decisions, alongside a global exhibitions business.
Something off on this page? Send us feedback.
Supplies professional data, analytics and workflow tools through Risk, Scientific, Technical & Medical, Legal and Exhibitions. Proprietary content underpins recurring digital products, while the live-events business remains dependent on in-person activity.
Provides professional information, analytics and decision tools through Risk, Scientific, Technical & Medical, Legal, and Exhibitions. LexisNexis supports legal and risk workflows, Elsevier supplies research and clinical information, and RX operates live events for customers across more than 180 countries.
Combines proprietary content and industry data with algorithms, technology and customer workflows. Acquisitions add datasets and technical capabilities, while the long-term migration from print to electronic products has made most information businesses digitally deliverable.
Recurring professional use depends on the quality and lawful use of scientific, legal, insurance, identity and public-record data. Scholarly-publishing pricing, government-data contracts and services for fossil-fuel industries remain sources of stakeholder criticism, while Exhibitions remains exposed to disruptions affecting in-person events.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 10, 2026 | Cowen & Co. | Initiate | Rating: — | |
| Apr 8, 2026 | Citigroup | Upgrade | ||
| Mar 14, 2025 | Barclays | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $293.1M · Total debt $11.87B · Total assets $20.03B · Shareholders' equity $1.65B
- Revenue
- $6.49B
- Operating income
- $2.10B
- Net income
- $1.56B
Reported in GBP, converted at the latest exchange rate
HistoryDividendAnnual yield
| Institutions | ≥ 4.71% | 85.75M ADS | |
|---|---|---|---|
| 447 holders · as of Jun 30, 2026 | |||
| Other | ≤ 95.29% | 1.73B ADS | |
| remainder | |||
1.82B ADS as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Institutional filings for RELX/35 (100% of the company) are not on file here, so the institutional figure is a floor.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Capital International InvestorsInstitution | 0.48% | 8.78M ADS | as of Jun 30, 2026 |
Morgan StanleyInstitution | 0.36% | 6.57M ADS | as of Jun 30, 2026 |
Arrowstreet Capital, Limited PartnershipInstitution | 0.35% | 6.28M ADS | as of Jun 30, 2026 |
Bank of America Corp /DE/Institution | 0.21% | 3.88M ADS | as of Jun 30, 2026 |
Goldman Sachs Group IncInstitution | 0.20% | 3.58M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Thomson Reuters
Westlaw anchors the closest legal-research and workflow rivalry
- Verisk Analytics
Insurance data and analytics across underwriting, claims, and fraud
- Clarivate
Research discovery and analytics built around Web of Science
- S&P Global
Commodity and industry intelligence through Platts and market data
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| RELX (ADR) | $32.86 | −1.65% | $58.33B | 20.2 | — | 4.5 | +1.0% |
| Thomson Reuters | $93.78 | −1.73% | $41.66B | 25.5 | 19.8 | 5.3 | +7.0% |
| Verisk Analytics | $171.05 | −0.56% | $22.39B | 26.4 | 20.9 | 7.1 | +4.4% |
| Clarivate | $1.88 | −2.59% | $1.23B | — | 2.6 | 0.5 | −5.5% |
| S&P Global | $402.91 | −0.39% | $119.24B | 24.6 | 21.3 | 7.4 | −2.1% |
| Median | 25.5 | 20.4 | 6.2 | +1.2% |